Hitomi (ASTRO-H) X-ray Astronomy Satellite

The Hitomi (ASTRO-H) mission is the sixth Japanese x-ray astronomy satellite developed by a large international collaboration, including Japan, USA, Canada, and Europe. The mission aimed to provide the highest energy resolution ever achieved at E  >  2  keV, using a microcalorimeter instrument, and to cover a wide energy range spanning four decades in energy from soft x-rays to gamma rays. After a successful launch on February 17, 2016, the spacecraft lost its function on March 26, 2016, but the commissioning phase for about a month provided valuable information on the onboard instruments and the spacecraft system, including astrophysical results obtained from first light observations. The paper describes the Hitomi (ASTRO-H) mission, its capabilities, the initial operation, and the instruments/spacecraft performances confirmed during the commissioning operations for about a month

Mapping of progressive loss of acetylcholinesterase activities in early- and late-onset Alzheimer\u27s disease.

The 10th conference on Alzheimer\u27s disease and related disorders

PET monitoring of donepezil therapy in patients with Alzheimers

The 12th International Symposium on Radiopharmacolog

Non-invasive Measurements of Acetylcholinesterase Activity with Normalized [11C]MP4A-PET Images for Dementia Diagnosis

10th Annual Meeting of the Organization for Human Brain Mappin

Positron emission tomographic measurement of acetylcholinesterase activity in Frontotemporal Dementia with Parkinsonism linked to Chromosome 17.

The Movement Disorder Society’s 8th International Ciongress of Parkinson’s Disease and Movement Disorders, Rome, June 13-17, 200

The SPM analysis of [11C]MP4A PET revealed pronounced loss of thalamic acetylcholinesterase activity in progressive supranuclear palsy

10th International Congress of Parkinson\u27s Disease and Movement Disorder

Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET

Acetylcholinesterase (AChE) activities in the brain of three patients with AD were measured once before and once during donepezil treatment (5mg/d in two patients, 3mg/d in one patient) using PET and N-[11C] methylpiperidin-4-yl acetae. Donepezil reduced K3 values,showed some degree of symptomatic improvement, and it was concluded that this improvement was likely caused by improved cholinergic activity by inhibition of AChE in the brain

Brain Cholinergic Function in Dementia with Lewy Bodies and Alzheimers Disease

The 5th International Conference on Progress in Alzheimers and Parkinsons Diseas